Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Sensipar (Cinacalcet) – US: District Court Delaware: Obviousness type double patenting does not require later-issued patent with shorter term to abridge term of earlier-granted patent with longer term: Brigham and Women’s Hospital et al v Teva et al (Docket Report) (PatLit)

Tarka (Trandolapril / Verapamil) – US: District Court New Jersey: Sanofi, Abbott win trial over Glenmark’s generic Tarka (GenericsWeb) (IPBiz)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

New rules eyed for election of WHO Director General (IP Watch)

WHO future in question; debate over industry representation (IP Watch)

IP’s place in the fight against the spread of malaria (Afro-IP)

New guide to TRIPS health provisions in FTAs (IP Watch)

EU Commission looking at generics and patents (IP finance) (GenericsWeb)

India: EU-India closer to FTA-hampered public health regime? (Spicy IP)

India: Delhi Patent Office refuses Warner-Lambert’s application claiming topical formulation of Pfizer’s potential potassium channel opener for treatment of alopecia (ipfeathers)

India: Chennai Patent Office refuses Novartis’ application claiming mixture of anti-oxidant with oxidation sensitive macrolide everolimus (ipfeathers)

Kenya: High Court enjoins UN in case against generic ARVs ban (GenericsWeb)

US government urges WHO to support Medicines Patent Pool: Extract of US intervention on draft WHO HIV/AIDS strategy 2011-2015 (KEI)

US: Senators let FDA know their intent regarding data exclusivity provisions of PPACA (Patent Docs)

US: You can’t cure that.  It’s the law. – Health Care Reform Bill (Patent Baristas)

US: Academic study supports longer data exclusivity term for conventional drugs (Patent Docs)

US: PTO sued after denying ‘mildly tardy’ second interim PTE request: Genetics & IVF Institute v Kappos (FDA Law Blog)

US: AMP v USPTO – Appellees’ brief (Patent Docs)

Products

Avodart (Dutasteride) – US: GlaxoSmithKline file patent infringement complaint against Anchen following Para IV certification (Patent Docs) (GenericsWeb)

Cozaar / Hyzaar (Losartan) – US: High Court denies Apotex petition on 180-day exclusivity: Apotex v Sebelius (FDA Law Blog) 

Fosrenol (Lanthanum) – US: Shire Canada file patent infringement suits against Alkem in N D Illinois and S D New York following Para IV certification filing (Patent Docs)

Lexapro (Escitalopram) – US: Apotex seeks to trigger 180-day exclusivity for generic Lexapro tablets (FDA Law Blog) (Patent Docs)

Lyrica (Pregabalin) – US: Pfizer files patent infringement complaint against Novel in response to Para IV certification (Patent Docs)

Olmesartan medoxomil / Hydrochlorothiazide – UK: EWHC decision in Daiichi Sankyo appeal against SPC refusal now available (The SPC Blog)

Pradaxa (Dabigatran) – India: Application for Dabigatran polymorphic form II refused under S. 15 (patentcircle) (ipfeathers)

Precose (Acarbose) – US: Mylan receives approval for generic version of Precose tablets (SmartBrief)

Sanctura (Trospium) – US: Allergan files patent infringement suit against Sandoz following Para IV certification filing (Patent Docs)

Sensipar (Cinacalcet) – US: District Court Delaware: Obviousness type double patenting does not require later-issued patent with shorter term to abridge term of earlier-granted patent with longer term: Brigham and Women’s Hospital et al v Teva et al (Docket Report) (PatLit)

Tarka (Trandolapril / Verapamil) – US: District Court New Jersey: Sanofi, Abbott win trial over Glenmark’s generic Tarka (GenericsWeb) (IPBiz)

Taxotere (Docetaxel) – US: Aventis files patent infringement complaint against Sandoz following Para IV certification filing (Patent Docs)

Valsartan – Denmark: Novartis and Teva settlement in Denmark – the terms (The SPC Blog)

Valturna (Aliskiren / Valsartan) – India: Patent Office revokes Novartis’ patent claiming single-pill combination of Aliskiren and Valsartan (ipfeathers)

VFEND (Voriconazole) – US: Pfizer files patent infringement complaint against Sandoz in response to Para IV certification (Patent Docs)

Vibativ (Telavancin) – India: Delhi Patent Office rejects national phase application claiming hydrochloride salt of Telavancin (ipfeathers)

Yaz (Drosperinone / Ethinyl estradiol) – US: Bayer Schering files patent infringement complaints against Sun Pharmaceuticals and others in New Jersey and Nevada following Para IV certification filing (Patent Docs)

Yaz (Drosperinone / Ethinyl estradiol) – India: Chennai Patent Office refuses Bayer Schering’s patent application claiming contraceptive combination formulation (ipfeathers)